Sandoz Launches An Exclusive Remodulin Rival In The US
Sandoz has claimed the first US launch of a generic rival to Remodulin with 180-day exclusivity, following a settlement deal struck with United Therapeutics four years ago.
Sandoz has claimed the first US launch of a generic rival to Remodulin with 180-day exclusivity, following a settlement deal struck with United Therapeutics four years ago.